Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 14
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Emergent BioSolutions Inc
EBS
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.92
-0.06
-0.86%
Últ. Act.: Oct 13, 7:38 PM
$6.86
-0.12
-1.72%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Emergent BioSolutions Financials
Emergent BioSolutions (EBS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million to $645.000 million-$675.000 million vs $733.050 million estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Q2 Adj. EPS $0.60 Beats $0.11 Estimate, Sales $234.300M Beat $177.500M Estimate
Benzinga Newsdesk
PRO
Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est
Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million to $720.000 million-$760.000 million vs $735.000 million estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of $0.74 per share from
Benzinga Newsdesk
